French cancer research firm to build plant in Raleigh

Posted by on Mar 7, 2019

A French biomedical firm that uses gene-editing technology to develop cancer treatments, plans to invest $68 million in a Raleigh plant, officials said Thursday.

Cellectis will hire up to 200 people for the plant, which will be the company’s first North American manufacturing operation.

Founded in 1999, Cellectis takes healthy donor T-cells and uses gene editing to create “off-the-shelf” products for cancer patients, Bill Monteith, who will oversee the plant, said during a news conference at the State Capitol.

The state approved a Job Development Investment Grant for the company that will allow it to receive rebates of up to $2 million in state withholding taxes over 12 years if it meets annual investment and hiring targets.

Leave a Reply